November 15, 2013 | Medpace, a CRO offering therapeutically specialized clinical development, is on the auction block according to Reuters. Private equity firm CCMP Capital Advisors owns the company and has hired an investment bank to run an auction. Medpace has top line annual earnings of close to $100 million, and CCMP believes they could earn twelve times that--$1.2 billion--in a sale. Reuters